EUVIMEDEUVIMED entdecken
Crossref

Low-dose Andrographolide Synergizes With Cytarabine or Vincristine in Plasma Cell Neoplasm Cell Lines

Hiroki Doi, Hidehiko Akiyama, Taei Matsui, Yuko Abe, Sumie Fujii, Hideaki Matsuura, Yasuo Miura

Anticancer Research · 2026

DOI: 10.21873/anticanres.18181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Hiroki Doi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Biology, Fujita Health University School of Medical Sciences, Toyoake, Japan. Hauptthemen laut MEDLINE: Diterpenes, Cytarabine, Vincristine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Andrographolide (Andro), a diterpene lactone from Andrographis paniculata, induces apoptosis via reactive oxygen species (ROS)-dependent mitochondrial dysfunction but achieves low plasma concentrations because of its lipophilicity. We investigated whether low-dose Andro potentiates the cytotoxicity of the mechanistically distinct agents cytarabine (Ara-C) and vincristine (VCR) in plasma cell neoplasm cell lines. MATERIALS AND METHODS: Human plasma cell neoplasm cell lines H929 and ARH77 were treated with Andro alone or in combination with Ara-C or VCR. Cell viability was assessed in dose- and time-response experiments, and pharmacologic interactions were quantified using the combination index (CI) method. Apoptosis was evaluated by Annexin V staining, and cell-cycle distribution was analyzed to examine mechanistic complementarity. RESULTS: Andro decreased viability in a dose- and time-dependent manner (IC50 at 48 h: 3.4 μM in H929; 7.5 μM in ARH77). Combining Andro with Ara-C or VCR further reduced viability; in H929 cells, all combination conditions yielded CI values

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiterpenesCytarabineVincristineAntineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaHumansDrug SynergismApoptosisCell Line, TumorCell SurvivalDose-Response Relationship, DrugReactive Oxygen Species

Stichwörter der Autor:innen

Andrographis paniculataChou-Talalay methodandrographolideapoptosiscombination index (CI)plasma cell neoplasm cells

Substanzen

DiterpenesandrographolideCytarabineVincristineReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Cellular and Molecular Biology, Fujita Health University School of Medical Sciences, Toyoake, Japan.
  • Department of Medical Laboratory Sciences, Faculty of Health and Medical Sciences, Aichi Shukutoku University, Nagakute, Japan.
  • Faculty of Medical Technology, Fujita Health University School of Medical Sciences, Toyoake, Japan.
  • Department of Blood Transfusion, Fujita Health University Hospital, Toyoake, Japan.
  • Department of Transfusion Medicine and Cell Therapy, Fujita Health University School of Medicine, Toyoake, Japan.
  • Department of Cellular and Molecular Biology, Fujita Health University School of Medical Sciences, Toyoake, Japan; ym58f5@kuhp.kyoto-u.ac.jp.

Zitieren

APA

Doi, H., Akiyama, H., Matsui, T., Abe, Y., Fujii, S., Matsuura, H., & Miura, Y. (2026). Low-dose Andrographolide Synergizes With Cytarabine or Vincristine in Plasma Cell Neoplasm Cell Lines. Anticancer Research. https://doi.org/10.21873/anticanres.18181

Vancouver

Doi H, Akiyama H, Matsui T, Abe Y, Fujii S, Matsuura H, et al. Low-dose Andrographolide Synergizes With Cytarabine or Vincristine in Plasma Cell Neoplasm Cell Lines. Anticancer Research. 2026. doi:10.21873/anticanres.18181

BibTeX
@article{Doi2026,
  author = {Doi, Hiroki and Akiyama, Hidehiko and Matsui, Taei and Abe, Yuko and Fujii, Sumie and Matsuura, Hideaki and Miura, Yasuo},
  title = {Low-dose Andrographolide Synergizes With Cytarabine or Vincristine in Plasma Cell Neoplasm Cell Lines},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18181}
}
Kostenlos starten →